Decade-Long Prodrome on Neuroimaging: Unique Insight into Probable Corticobasal Degeneration.
Tai XY. et al, (2025), Mov Disord
Working memory filtering at encoding and maintenance in healthy ageing, Alzheimer’s and Parkinson’s disease
Toniolo S. et al, (2025), Scientific Reports, 15
Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.
Gonzalez-Robles C. et al, (2025), Mov Disord
Single extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson’s disease
Yan S. et al, (2025), Cell Reports Medicine, 6, 101999 - 101999
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease
Yan S. et al, (2024), JAMA Neurology, 81, 59 - 59
Detailed Analysis of ITPR1 Missense Variants Guides Diagnostics and Therapeutic Design.
Tolonen JP. et al, (2023), Mov Disord
Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.
Park J. et al, (2023), Genet Med, 25
Normal and pathogenic variation of RFC1 repeat expansions: implications for clinical diagnosis.
Dominik N. et al, (2023), Brain
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
Foltynie T. et al, (2023), Brain, 146, 2717 - 2722
Monitoring α-synuclein ubiquitination dynamics reveals key endosomal effectors mediating its trafficking and degradation
Zenko D. et al, (2023), Science Advances, 9
Methodological considerations in neuronal extracellular vesicle isolation for α-synuclein biomarkers
Yan S. et al, (2023), Brain
Alternating Magnetic Field-Promoted Nanoparticle Mixing: The On-Chip Immunocapture of Serum Neuronal Exosomes for Parkinson’s Disease Diagnostics
Sharafeldin M. et al, (2023), Analytical Chemistry, 95, 7906 - 7913
Multiplexed Profiling of Extracellular Vesicles for Biomarker Development
Jiang C. et al, (2022), Nano-Micro Letters, 14
The Phenotypic Continuum of ATP1A3-Related Disorders.
Vezyroglou A. et al, (2022), Neurology, 99, e1511 - e1526
Initiation and progression of α-synuclein pathology in Parkinson’s disease
Tofaris GK., (2022), Cellular and Molecular Life Sciences, 79
Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study
Pereira MF. et al, (2022), BMJ Neurology Open, 4, e000214 - e000214
Treatment Selection in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease: The Search for the Ideal Neuroprotective Drug
Gonzalez-Robles C. et al, (2022), MOVEMENT DISORDERS, 37, S329 - S329
Phenotypic manifestation of α-synuclein strains derived from Parkinson’s disease and multiple system atrophy in human dopaminergic neurons
Tanudjojo B. et al, (2021), Nature Communications, 12